Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and anlotinib in advanced NSCLC with EGFR uncommon mutations
NCT04790409Phase 2Completed
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2019
- Primary completion
- Sep 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, anlotinib in non-small cell lung cancer (NSCLC), sponsored by Zhejiang Cancer Hospital. Started Aug 2019; status: completed.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04790409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04790409.